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TO THE EDITOR
In murine cutaneous leishmaniasis,
control of infection is associated
with both IFN-g–producing CD4þ Th1
and CD8þ Tc1 cells. Secreted IFN-g
promotes host defense by inducing
nitric oxide release from activated
macrophages (MF). The key player for
the induction of Th1/Tc1-dependent
immunity in leishmaniasis is IL-12 from
Leishmania major-infected dendritic
cells (DC), but not from Mf (von Stebut
et al., 1998). Only Leishmania-infected
DCs were capable of restimulating
L. major-specific CD8þ T cells to
induce IFN-g secretion (Belkaid et al.,
2002). Major histocompatibility com-
plex (MHC) class I/ mice or those
depleted from CD8þ T cells did not
heal (Belkaid et al., 2002). Thus, DC-
mediated induction of L. major-specific
CD8þ T cells is absolutely required for pri-
mary immunity in murine leishmaniasis.
In general, priming of CD8þ T cells
is induced by presentation of peptides
degraded by the proteasome and bound
to MHC class I (Yewdell and Bennink,
1999; Kloetzel, 2001). The 20S core
complex of the proteasome is com-
posed of 14 nonidentical subunits,
which form four stacked rings of seven
different subunits each. The hydrolyz-
ing activity is conferred by three of
these seven b subunits in the two inner
rings b1, b2, and b5 (Groll et al., 1997).
There are two different types of protea-
somes: the constitutive form and the
IFN-g–inducible immunoproteasome.
IFN-g induces the synthesis of immu-
nosubunits b1i (LMP2), b2i (MECL-1),
and b5i (LMP7) all of which replace the
constitutive b1, b2, and b5 subunits in
the 20S core proteasome (Frentzel
et al., 1994). The b5i/LMP7 subunit is
essential for an accelerated upregula-
tion of the functional immunoprotea-
some catalytic core complex (Heink
et al., 2005). Constitutive proteasomes
and immunoproteasomes have distinct
proteolytic activities (Boes et al., 1994;
Eleuteri et al., 1997), and the immuno-
proteasome can enhance the presenta-
tion of some epitopes (Schwarz et al.,
2000), but abrogate the presentation of
others (Morel et al., 2000).
Previously, it has been shown
(Bertholet et al., 2006) that L. major
antigens are presented to CD8þ T cells
in a transporter associated with antigen
processing-independent pathway. In vitro,
antigen presentation was also not
influenced by constitutive proteasomes
(Bertholet et al., 2006). Thus, it remains
unclear how parasite antigen proces-
sing in the MHC class I pathway in DC
is regulated. The Th1/Tc1-dominated
immunity of resistant mouse strains
(e.g., C57BL/6) as well as humans is
characterized by high levels of IFN-g.
Confirmingly, we detected immuno-
proteasome subunit expression during
L. major infections by western blot of
infected DC in vitro and in draining
lymph nodes (dLN) of infected C57BL/6
mice in vivo (Figure 1a and b) (Tenzer
et al., 2004). This prompted us to
investigate the role of the IFN-g–in-
duced immunoproteasome in L. major
infections in vivo using LMP7-deficient
mice.
Natural transmission of L. major
infections was mimicked experimentally
by intradermal infection with B1,000
metacyclic L. major promastigotes (Belk-
aid et al., 2000). Both, LMP7/ as well
as wild-type mice developed compar-
able disease progression with regard to
lesion sizes (Figure 1c). Lesion volumes
in week 6 and 9 correlated with parasite
burdens (Figure 1d), and the parasite
numbers in infected ears did not differ
between the strains. Similar levels of
antigen-specific IFN-g were secreted
by dLN cells from both strains at
different time points (Figure 1e). IL-10
was detected only at low levels.
Next, to investigate the ability of DC
from C57BL/6 or LMP7-deficient mice
to efficiently restimulate Tc1 cells, we
cocultured infected DC from both
mouse strains with isolated syngeneic
CD8þ T cells for 48 hours (Figure 2;
Supplementary Figure S1 online) and
determined secretion of IFN-g. Interest-
ingly, similar IFN-g levels of L. major-
specific CD8þ T cells were found and
additionally, T-cell proliferation did not
differ significantly (Figure 2). Despite
the fact that background T-cell prolif-
eration was higher when LMP7/ DC
were used, a significantly increased anti-
gen-specific T-cell proliferation was ob-
served upon coculture with infected bone
marrow–derived DC of either mouse
strain. Thus, restimulation of L. major-
specific CD8þ T cells by DC is indepen-
dent of the immunoproteasome.
To investigate the priming of CD8þ
T cells in the absence of a functional
immunoproteasome in vivo, dLN cells
from both strains were harvested at 4
weeks post infection. Proliferation was
analyzed using flow cytometry. In
C57BL/6 cells, an increase of the
antigen-specific proliferation of CD8þ
T cells compared with controls was
observed (Figure 2c). Similar prolifer-
ation of CD8þ T cells was detected
from LMP7-deficient mice after antigen-
specific restimulation. In addition,
we observed a comparable frequency
of IFN-g–positive CD8 T cells in the
dLN as well as ear lesions of C57BL/6
and LMP7/ mice (Figure 2d and e).
These data indicate that priming and
restimulation of CD8þ T cells in LMP7/
mice is comparable to that in immuno-
proteasome-competent mice.
Normally, priming of CD8þ T cells
for effective immune responses toward
antigens requires antigen processing
in a proteasome/immunoproteasome-
dependent manner (Cresswell, 2000;
Yewdell and Bennink, 2001). In the
present study, we found that the
immunoproteasome is dispensable forAbbreviations: DC, dendritic cells; dLN, draining lymph nodes
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MHC class I-restricted CD8þ T-cell
priming in vivo. Our findings are in
line with a recent paper by Bertholet
et al. (2006) reporting that antigen
presentation of L. major peptides to
CD8þ T cells is proteasome/transporter
associated with antigen processing-
independent (Bertholet et al., 2006).
Considering the distinct proteolytic
activities of the immunoproteasome
and the constitutively expressed protea-
some (Boes et al., 1994; Eleuteri et al.,
Figure 2. L. major-infected LMP7/ dendritic cells (DC) show a restimulatory capacity of antigen-specific CD8þ T cells comparable to wild-type DC.
(a) DC from LMP7/ and C57BL/6 mice were infected overnight with amastigotes of L. major (multiplicity of infection 10:1). Cells were harvested after
18 hours and infection rates determined. CD8þ T cells from L. major-infected C57BL/6 mice were added to DC at 5 105 per well (T cell/DC ratio 5:1).
IFN-g secretion was determined after 48 h. (b) CD8 T-cell proliferation was determined after addition of 3H-thymidine for the last 18 hours of the 48-hour
coculture. (c) Draining lymph node (dLN) cells of infected C57BL/6 or LMP7/ mice were harvested after 4 weeks, labeled with 5-(and-6)-carboxyfluorescein
diacetate (CFSE), plated at 1x106 cells per 200ml, and restimulated with medium or with Leishmania antigen (soluble Leishmania lysate (SLA), 25 mgml1).
Proliferation of CD4þ and CD8þ T cells was determined by flow cytometry on day 6. One representative experiment of two withX3 mice per group is shown.
All data are expressed as mean±SEM (n¼ 3, *Pp0.05, ***Pp0.002). (d, e) Draining lymph node (dLN) and inflammatory ear cells were harvested at week
4 and 6 post infection, plated at 5106 cells per 200ml, and stimulated for 4–6 hours using phorbol 12-myristate 13-acetate (PMA) (50 ngml1), ionomycin
(Iono, 500 ngml1), and Brefeldin A (1 mgml1). Cells were then stained and analyzed by flow cytometry. T cells were identified by CD3/CD8 staining, and the
percentage of IFN-gþ cells was calculated. (d) One of the several independent stainings in week 4 is depicted. (e) The frequency of IFN-g–producing CD8 T cells
was expressed as mean±SEM (n¼5). Stim., stimulation.
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Figure 1. Leishmania-resistant LMP7/ mice display no alterations in lesion sizes, parasite burdens, and cytokine profiles in L. major infections.
Bone marrow–derived dendritic cells (2 105 cellsml1) infected with L. major amastigotes at a cell/parasite ratio of 1:5, (a) and lymph nodes of L. major-infected
C57BL/6 mice (103 parasites) (b) were lysed at the time points indicated. Western blots for immunoproteasome subunits MECL (b2i), LMP2 (b1i), LMP7 (b5i),
and b-actin as loading control were performed as described (Tenzer et al., 2004). (b) Quantitative densitometry revealed an B2-fold upregulation for all
subunits within 6 weeks post infection. (c–e) LMP7/, and wild-type C57BL/6 mice were infected intradermally with physiological low-dose inocula of
L. major (103 metacyclic promastigotes) in both ears. (c) Lesion development was assessed weekly in three dimensions and expressed as mean±SEM
(nX5, pooled data from two independent experiments). (d) Ears were harvested 6 and 9 weeks post infection, and the number of parasites was assessed
using a limiting dilution assay. Dots represent numbers of parasites in individual ears and bars indicate means. (e) Lymph node cells were plated at 1106 cells
per 200 ml and restimulated with soluble Leishmania lysate. Cytokine release was determined after 48 hours by ELISA and expressed as mean±SEM
(nX9, pooled data from two independent experiments). p.i., post infection.
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Figure 2. For legend see page 1303.
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1997), presentation of L. major antigens
to CD8þ T cells appears to be indepen-
dent of these two major nonlyso-
somal protein degradation machineries,
implying the involvement of alternative
cytosolic pathways of cross-presentation
emcompassing protease candidates, such
as tripeptidyl peptidase II and nardilysin.
In summary, our data indicate that
despite the fact that CD8 responses are
highly effective in protecting against nat-
ural L. major infections, it remains unclear
how parasite epitopes are generated in
infected DC. Interestingly, recent data
suggest that priming of Leishmania-specific
CD4þ T cells is mediated by Langerinneg
dermal DCs, whereas Langerinþ dermal
DCs promote early CD8þ T-cell priming
(Brewig et al., 2009). A detailed under-
standing of the pathways utilized for pro-
cessing of L. major-derived CTL-epitopes
in the MHC class I pathway as well as
knowing which DC subset to target during
vaccination will be helpful for the devel-
opment of new vaccine candidates against
this important human pathogen.
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TO THE EDITOR
Epidermodysplasia verruciformis (EV) is
a rare, lifelong, autosomal recessive
skin disease (OMIM number 226400)
associated with an unusual susceptibil-
ity to infections with ubiquitous beta
human papillomaviruses (b-HPVs), but
not to infections with other pathogens,
including cutaneous and genital HPVs
of the alpha, gamma, mu, or nu genera
(Jablonska and Majewski, 1994; Orth,
2006).Abbreviations: EV, epidermodysplasia verruciformis; HPV, human papillomavirus
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